Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
allergies
Research
Holoclara wriggles into ph. 1, sets sights on immune disease
The drug candidate being tested, HC002, is an oral small molecule that was originally sourced from roundworms that live in our guts.
Darren Incorvaia
Dec 18, 2024 9:05am
Food allergy biotech DBV is running out of cash
Mar 8, 2024 10:30am
Could Dupixent find a new life targeting 'memory' B cells?
Feb 9, 2024 11:50am
Altamira lays off 25% of staff weeks after allergy spray spinoff
Dec 11, 2023 9:58am
Alladapt's 15-allergen drug desensitizes kids to multiple foods
Jun 13, 2023 8:15am
Third Harmonic braves IPO waters to fund ex-Novartis drug R&D
Aug 24, 2022 8:05am
